Roche to Skip Ahead to Late-Stage Study for Breast Cancer Drug

Roche Holding AG will skip a mid-stage study of an experimental immunotherapy for breast cancer and proceed directly to a phase 3 trial later this year.

The Swiss company will study MPDL3280A for triple-negative breast cancer, which is currently treated mostly with chemotherapy, spokeswoman Holli Dickson said in a phone interview. The drug will be tested in combination with chemotherapy.

The company will present results from an early-stage study of the drug at a cancer meeting in Philadelphia on April 20. Roche is competing with Merck & Co. to develop a drug for a segment of the breast cancer market that may reach as much as $5 billion in peak sales, according to Goldman Sachs Group Inc. analysts.

In triple-negative breast cancer, tumor cells don’t have estrogen or progesterone receptors and don’t have extra HER2 proteins or surplus copies of the HER2 gene. About 15 percent of breast-cancer patients have that type.

Roche’s drug already has U.S. Food and Drug Administration “breakthrough” status for bladder and lung cancers, which can lead to faster review and approval.

Before it's here, it's on the Bloomberg Terminal.